Search Results

AIA-PACK Troponin I is intended for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of cardiac troponin I (cTnl) in human serum and plasma on specific TOSOH AIA System analyzers. Measurements obtained by this device aid in the diagnosis of acute myocardial infarction (AMI).

Not Found

The provided document is a 510(k) clearance letter for the AIA-Pack® Troponin I Assay, dated December 23, 1998. It primarily confirms that the device is substantially equivalent to legally marketed predicate devices and is thus cleared for marketing.

However, this document does not contain the detailed information needed to answer the questions about acceptance criteria and study design. It is a regulatory clearance document, not a scientific study report.

Specifically, the document does not include:

• A table of acceptance criteria or reported device performance metrics like sensitivity, specificity, accuracy, etc.
• Information on sample sizes for test sets (or training sets).
• Details about data provenance (e.g., country of origin, retrospective/prospective).
• The number or qualifications of experts used to establish ground truth.
• Adjudication methods.
• Information on Multi-Reader Multi-Case (MRMC) comparative effectiveness studies.
• Details about standalone (algorithm-only) performance.
• The type of ground truth used (e.g., pathology, outcomes data).
• How ground truth for any training set was established.

To obtain this information, one would typically need to consult the full 510(k) submission, study reports, or peer-reviewed publications related to the AIA-Pack® Troponin I Assay. The provided document is merely the FDA's regulatory decision letter.

Ask a specific question about this device